Shares of Biocept Inc (NASDAQ:BIOC) ended Tuesday session in red amid volatile trading. The shares closed down -0.013 points or -2.17% at $0.587 with 43,337.00 shares getting traded. Post opening the session at $0.57, the shares hit an intraday low of $0.57 and an intraday high of $0.60 and the price vacillated in this range throughout the day. The company has a market cap of $14.55 million and the numbers of outstanding shares have been calculated to be 25.19 million shares.
Biocept Inc (BIOC) on Sept. 9, 2016 announced a research collaboration with Shilpa Gupta, Ph.D., Assistant Professor in the Hematology Oncology and Transplantation Division of the University of Minnesota to observe the utility of Biocept’s patented Target Selector™ liquid biopsy technology platform using circulating tumor cells (CTCs) to detect the expression of PD-L1 and androgen receptor (AR) in patients diagnosed with bladder and prostate cancers. The study will be conducted at the University of Minnesota Masonic Cancer Center. PD-L1 is expressed in multiple cancer types and its status is required to qualify patients for certain immuno-oncology therapeutics. AR expression is prevalent in patients with advanced prostate cancer.
“We are delighted to be working with Dr. Gupta, who is internationally recognized as the principal investigator for several high-impact clinical trials with novel targeted therapeutics and immunotherapy agents for patients with bladder and prostate cancers,” said Veena Singh, MD, Biocept’s Senior Vice President and Senior Medical Director. “Dr. Gupta has been an active speaker at national and international forums discussing the role of novel therapeutics for personalized medicine in prostate cancer.”
Dr. Gupta added, “Tissue sample collection and cystoscopy are the standard methods for detecting bladder and prostate cancers, and these methods are invasive and can be expensive. Biocept’s liquid biopsy tests have shown high concordance with tissue biopsies in detecting genetic mutations associated with multiple cancers, and this study is aimed at providing additional clinical support for the use of these tests specifically in bladder and prostate cancers.”
Shares of CytRx Corporation (NASDAQ:CYTR) ended Tuesday session in red amid volatile trading. The shares closed down -0.019 points or -3.18% at $0.567 with 1.37 million shares getting traded. Post opening the session at $0.59, the shares hit an intraday low of $0.56 and an intraday high of $0.59 and the price vacillated in this range throughout the day. The company has a market cap of $56.55 million and the numbers of outstanding shares have been calculated to be 96.94 million shares.
CytRx Corporation (CYTR) on Sept. 7, 2016 announced that it has reached its enrollment target of 132 patients for the company’s global Phase 2b clinical trial of aldoxorubicin in patients with previously treated small cell lung cancer (SCLC). The Phase 2b study is a randomized, comparative trial being conducted at 41 sites in the United States, Hungary and Spain.
“Patients with metastatic small cell lung cancer who have relapsed or are refractory to first-line chemotherapy have few treatment options,” said Steven A. Kriegsman, Chairman and CEO of CytRx. “Aldoxorubicin represents a potential new therapy to combat this aggressive form of cancer. The Phase 2b trial uses a lower dose of aldoxorubicin than our Phase 3 trial in soft tissue sarcoma, which may improve the tolerability and potentially allow patients to stay on treatment longer. We look forward to reporting the trial results once they are available.”
Because of the unmet medical need for patients with second-line SCLC, if the global Phase 2b clinical trial results are positive, CytRx intends to meet with the U.S. FDA to discuss the regulatory pathway for the submission of a New Drug Application for aldoxorubicin in this patient population.